Within one week of initiating first-line treatment with nivolumab for melanoma, the patient experiences acute renal allograft rejection, renal failure, and concurrent diabetic ketoacidosis [41], suggesting a potential association between the use of anti-PD-1 antibodies and allograft rejection. This evidence concerns the gene PDCD1 and diabetic ketoacidosis.